The University of Alabama at Birmingham (UAB) Comprehensive Cancer Center (CCC) has a long history of participation within the nation's cancer related Clinical Trials Cooperative Group Program. Specifically, UAB was a founding member of the GOG, and has been a member of RTOG, ECOG, ACRIN. CALGB, NSABP, and SWOG. The UAB CCC now submits this proposal to become a Lead Academic Participating Site, specifically named the NCTN Deep South Research Consortium, in the NCI's newly restructured National Clinical Trials Network (NCTN) Program. It is our intention to continue as a leading contributor of scientific leaders and clinical trial participants to the NCTN Program in th U.S. and particularly in the Southeast. To accomplish this overall vision, we propose the following specific aims: 1) To further enhance the involvement of existing UAB CCC scientific leadership in NCTN Center related clinical and translational research and to develop the next generation of NCTN Center scientific leaders within the UAB CCC, and 2) To further refine a clinical trials process within the UAB CCC that optimizes accrual of potentially eligible cancer patients and patients at risk for cancer to NCTN Center clinical trials. We include in this proposa a detailed description of our NCI cooperative group scientific and patient accrual contributions and accomplishments, a leadership and organizational structure for our proposed Consortium, and how we intend to utilize existing UAB CCC infrastructure to achieve our aims. We also include a detailed description of our proposed Junior Investigator Recruitment and Mentoring Program.

Public Health Relevance

This proposal will ensure that the NCTN Program is provided better access to UAB CCC clinical and translational investigators with a broad interest in cancer prevention and control, cancer biology, and experimental therapeutics. Importantly, this proposal will also provide NCTN clinical trials better access to a patient population that based upon its demographics and socioeconomic status is distinct from other areas in the country.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Mooney, Margaret M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Alabama Birmingham
Obstetrics & Gynecology
Schools of Medicine
United States
Zip Code
Phippen, N T; Secord, A A; Wolf, S et al. (2017) Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) study. Gynecol Oncol 147:98-103
Miller, Caela R; Chappell, Nicole P; Sledge, Caitlin et al. (2017) Are different methotrexate regimens as first line therapy for low risk gestational trophoblastic neoplasia more cost effective than the dactinomycin regimen used in GOG 0174? Gynecol Oncol 144:125-129
Sekeres, Mikkael A; Othus, Megan; List, Alan F et al. (2017) Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol 35:2745-2753
Eisfeld, Ann-Kathrin; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2017) Mutational Landscape and Gene Expression Patterns in Adult Acute Myeloid Leukemias with Monosomy 7 as a Sole Abnormality. Cancer Res 77:207-218
Agarwala, Sanjiv S; Lee, Sandra J; Yip, Waiki et al. (2017) Phase III Randomized Study of 4 Weeks of High-Dose Interferon-?-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Gro J Clin Oncol 35:885-892
Smith, M R; Hong, F; Li, H et al. (2017) Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by (90)Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499. Leukemia 31:517-519
Truong, Minh Tam; Zhang, Qiang; Rosenthal, David I et al. (2017) Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Locally Advanced Head and Neck Carcinoma: NRG Oncology Radiatio Int J Radiat Oncol Biol Phys 97:687-699
Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2017) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv 11:32-40
Ng, Chaan S; Zhang, Zheng; Lee, Susanna I et al. (2017) CT Perfusion as an Early Biomarker of Treatment Efficacy in Advanced Ovarian Cancer: An ACRIN and GOG Study. Clin Cancer Res 23:3684-3691
Pine, Alexander B; Lee, Eun-Ju; Sekeres, Mikkael et al. (2017) Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United States. Transfusion 57:289-295

Showing the most recent 10 out of 46 publications